Business / Finance

RSS

Bio-Path 2011 net loss increases to $2,363,344

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year ended December 31, 2011.

4 Apr 2012

Ensign subsidiary acquires Zion's Way Home Health and Hospice

The Ensign Group, Inc., announced today that an Ensign subsidiary has acquired Zion's Way Home Health and Hospice, a well-regarded home health and hospice agency based in St. George, Utah, with branch offices in the cities of Kanab, Utah and Page, Arizona. The acquisition was effective as of April 1, 2012.

3 Apr 2012

Meda opens China affiliate based in Beijing

Meda has established an affiliate in Hong Kong. At the end of last year, Meda opened its China affiliate based in Beijing. Meda will begin by commercializing two of its well-established products in Hong Kong; Elidel for the treatment of atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis.

3 Apr 2012

Ventas acquires Cogdell

Ventas, Inc. announced today that it has completed its previously announced acquisition of Cogdell Spencer Inc.

3 Apr 2012

Organovo 2011 total revenues increase 61% to $968,513

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today reported the financial results for the year ended December 31, 2011.

3 Apr 2012

Humana acquires Arcadian Management Services

Humana Inc. announced today that it has completed its previously announced acquisition of Arcadian Management Services, an Oakland, Calif.-based company that, through its affiliates, operates Medicare Advantage HMO plans.

3 Apr 2012

CompCare's 2011 revenues increase to $71,210,000

Comprehensive Care Corporation, a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S., is pleased to announce that its revenues for 2011 more than doubled to $71,210,000 compared to revenues of $35,214,000 in 2010.

2 Apr 2012

Teva reports successful outcome of three debut financings

Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.

2 Apr 2012

Linkwell to acquire Metamining Nevada

Linkwell Corporation, a developer, manufacturer and distributer of disinfectant healthcare products in China, announced today it has entered into a definitive share exchange agreement with Metamining Inc. to acquire Metamining Nevada, Inc., as a wholly owned subsidiary,

2 Apr 2012

AlloCure closes $25 million Series B venture financing

AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing.

2 Apr 2012

Accountable Healthcare completes acquisition of MED-STAFF Oklahoma

Accountable Healthcare Holdings Corp, a provider of quality healthcare staffing solutions, today announced that it completed the acquisition of Tulsa, Oklahoma based MED-STAFF Oklahoma, a predominately Travel Nurse focused business that specializes in placing registered nurses, physical and occupational therapists and diagnostic imaging techs in all fifty U.S. states.

2 Apr 2012

Encision completes private placement of 1,500,000 shares of common stock

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, announced today that it had completed a private placement of 1,500,000 shares of its common stock.

2 Apr 2012

Bruker acquires SkyScan

Bruker Corporation today announced that it has acquired all of the shares of SkyScan N.V., a scientific instruments company located near Antwerp, Belgium. Financial details were not disclosed. For the remainder for 2012, the acquisition of SkyScan is expected to add approximately $13 million to Bruker's revenue and to be accretive to EPS by about $0.01.

2 Apr 2012

Vanguard closes private placement of $375 million 7.750% Senior Notes

Vanguard Health Systems, Inc. announced today that its wholly-owned subsidiaries, Vanguard Health Holding Company II, LLC and Vanguard Holding Company II, Inc. (together with VHS Holdco II, the "Issuers"), closed their private placement of an aggregate principal amount of $375.0 million of 7.750% Senior Notes due 2019.

31 Mar 2012

Vasomedical reports record revenue of $23.49M for period ended December 31, 2011

Vasomedical, Inc., a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today announces its operating results for the seven months ended December 31, 2011.

31 Mar 2012

PENTAX Lifecare acquires Digital Endoscopy

PENTAX Lifecare, a division of Hoya Corporation, today announced the acquisition of Digital Endoscopy GmbH, which will expand PENTAX's global R&D capabilities.

31 Mar 2012

PLC Systems fourth quarter total revenues increase to $189,000

PLC Systems Inc., a company focused on innovative medical device technologies, today reported financial results for the three- and twelve month periods ended December 31, 2011.

31 Mar 2012

Food Technology Service fourth quarter revenue increases 24.7% to $962,297

Food Technology Service, Inc. today announced financial results for the year ending December 31, 2011. Food Technology Service, Inc. had revenue of $3,744,546 in 2011 which is a 24.4 percent increase over 2010 revenue of $3,010,320.

31 Mar 2012

Feihe International fourth quarter sales increase 42.1% to $87.0M

Feihe International, Inc., one of the leading producers and distributors of premium infant formula, milk powder and soybean, rice and walnut products in China, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2011.

31 Mar 2012

Galectin Therapeutics fourth quarter net loss increases to $3.7 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2011.

31 Mar 2012